Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study

Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics committee and the Clinical Trials Registry to begin the world's first Phase 2a take-home LSD microdosing trial in patients with Major Depressive Disorder (MDD).

MDD is reportedly the leading cause of global disability, with over 260 million people affected. 

MindBio is viewed as one of the businesses most committed to the advancement of LSD microdosing trials, a psychedelic-based treatment that “proposes to be a globally scalable solution to treating mental health conditions,” as CEO Justin Hanka defined it. 

Continue reading HERE.

Novel DMT Compound For Anxiety Shows Clinical Progress: Robust Effects Within 2 Minutes

Canadian clinical-stage psychedelics company Cybin Inc. CYBN announced that the first group of participants have been dosed with its proprietary deuterated DMT molecule, CYB004, in an ongoing three-part Phase 1 trial evaluating both intravenous DMT and CYB004 in healthy volunteers. 

CYB004’s robust psychedelic effects were seen within two minutes of administration, reaching a peak at about thirteen minutes. No safety concerns were reported from the dosed group.

Part 3 (C) of the Phase 1 trial has a crossover design set to evaluate IV bolus plus infusion regimens of CYB004 in up to two cohorts. Continue reading HERE. 

Trial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin Session, Plus Tryp’s IND Application For IBS Treatment

Positive long-term follow-up data from Sunstone Therapies’ investigator-initiated Phase 2 study assessing COMPASS Pathways’ CMPS synthetic psilocybin COMP360 paired with psychological support in cancer patients with Major Depressive Disorder (MDD) is out.

57% of patients sustained remission of depression, and 64% had a robust clinical response, at 18 months following administration of a single 25mg psilocybin dose paired with psychological support. Continue reading HERE.

Meanwhile, Tryp Therapeutics TRYP submitted an Investigational New Drug (IND) application to the FDA for its planned Phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients over 21 suffering from Irritable Bowel Syndrome (IBS) at Massachusetts General Hospital (MGH). More on the trial HERE.

The Milestone Round

• Irwin Naturals IWINF shared its yearly financial results and a business update.

• PharmAla Biotech and Vitura Health’s CEOs provided details on their new Australian psychedelics business venture.

• Vertical Peak Holdings SPLIF and Neural Therapeutics closed the latter’s spin-out through an arrangement under the BC Business Corporations Act.

• The MindMed MNMD team published a report by an independent consultant firm that would support the company’s proposed development plan facing the FCM alternative. 

• Small Pharma DMTTF was granted several patents, with more expectedly coming soon, covering next-gen psychedelic compounds.

• Enveric Biosciences ENVB received a US Notice of Allowance for its patent application covering composition of matter and use methods of its prodrug psilocin derivatives.

• Private biotech Psilera selected PSIL-006 out of its non-hallucinogenic drug portfolio and is getting ready to move forward to the clinical stage.

• States reform update includes North Carolina’s $5 million research grants, California’s rescheduling bill following federal update and Maine’s psilocybin program, while Colorado Gov. Polis ratified a regulations bill and Minnesota’s Walz did so on a large-scale health bill including psychedelics-related provisions; plus details on Washington’s state-mandated psilocybin clinical trial.

• A Denver business is offering psilocybin mushroom spores syringes for research purposes.

• Magic mushroom microdosing: Why the trend is catching on and what the practice is all about

• Numinus Wellness NUMIF CEO Nyquvest elaborated on the company’s MDMA therapy strategy.

• Miscellaneous this week includes a somewhat old (but gold) Johns Hopkins-led research assessing the effects of MDMA on octopuses, and bodybuilding legend Dorian Yates’ ayahuasca journey. 

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance:

AdvisorShares Psychedelics ETF PSIL opened Monday, May 29 at $1.71, following Friday 26’s closing at $1.73. Opening price on Monday 22 was $1.76, yet the prior two Mondays’ openings were $1.70 and $1.74, which makes a somewhat constant trend. 

The week’s highest was $1.82 as seen on Wed. 24, which surpassed prior two weeks’ highest $1.77 and $1.78, respectively. The week’s lowest was $1.69, achieved some time within Friday 26 and also similar to the former two weeks’ lowest at $1.71 and $1.72.

For this ETF, the yearly price range is set between $4.35 and $1.65.